1 in parallel for a 15 time point, preclinical
pharmacokinetic study.
2 el from the NC formulation in an independent
pharmacokinetic study.
3 dice patients and can be used to support its
pharmacokinetic study.
4 y, and accuracy and was applied to support a
pharmacokinetic study.
5 tion was supported by the results of a 3-day
pharmacokinetic study.
6 ized, one treatment, one period, single dose
pharmacokinetic study.
7 This was an open-label
pharmacokinetic study.
8 nd in plasma is presented as a first step in
pharmacokinetic studies.
9 eived a single 400-mg dose of vorinostat for
pharmacokinetic studies.
10 er profiled in additional in vivo models and
pharmacokinetic studies.
11 r during dissection and assay in traditional
pharmacokinetic studies.
12 e and reasonable oral bioavailability in dog
pharmacokinetic studies.
13 e for the reduction of the use of animals in
pharmacokinetic studies.
14 applied to the analysis of plasma samples in
pharmacokinetic studies.
15 t advantage in high-throughput screening for
pharmacokinetic studies.
16 ns is important both for epidemiological and
pharmacokinetic studies.
17 topic incorporations for drug metabolism and
pharmacokinetic studies.
18 g microfluidic devices for advanced cell and
pharmacokinetic studies.
19 xyphenyl)-4H-chromen-4-one) was selected for
pharmacokinetic studies.
20 , elimination) and PBPK (physiological-based
pharmacokinetic) studies.
21 tro pharmacokinetics experiments and in vivo
pharmacokinetics studies.
22 tro pharmacokinetics experiments and in vivo
pharmacokinetics studies.
23 earance and poor oral bioavailability in its
pharmacokinetics studies.
24 ategy has potential applications in clinical
pharmacokinetics studies.
25 Following
pharmacokinetic studies,
23 was further evaluated in HCT
26 pounds exhibit poor systemic exposure in rat
pharmacokinetic studies after oral dosing.
27 Ten patients participated in an extensive
pharmacokinetic study after week 50.
28 Pharmacokinetic studies allowed the identification of th
29 ons in basic biochemical research as well as
pharmacokinetic studies and biomarker discovery.
30 Pharmacokinetic studies and ERBB-receptor expression and
31 on of atrazine and its metabolites in future
pharmacokinetic studies and for the subsequent developme
32 analyze biological samples from both in vivo
pharmacokinetic studies and in vitro microsomal/S9 stabi
33 We then carried out
pharmacokinetic studies and measured cortical nitric oxi
34 corresponding weight bands who consented to
pharmacokinetic studies and received the studied doses.
35 oups are necessary to compare results across
pharmacokinetic studies and to assess potential subgroup
36 Pharmacokinetic studies and UGT1A1 genotyping were perfo
37 to "OROS-methylphenidate") were conducted: a
pharmacokinetic study and a pharmacodynamic study.
38 (Pred) regimen first in a phase I safety and
pharmacokinetic study and then in a phase II assessment
39 combinant monoclonal antibodies in serum for
pharmacokinetics studies and it can also be used where s
40 ike molecule and has a half-life of 1 h in a
pharmacokinetics study and a reasonable oral availabilit
41 Plasma samples were obtained for
pharmacokinetic studies,
and a population approach via n
42 e, both compounds were bioavailable in mouse
pharmacokinetic studies,
and compound 6 is the first EGF
43 re-activity relationships, safety, metabolic/
pharmacokinetic studies,
and mechanistic investigation a
44 day 14 of each phase, blood was sampled for
pharmacokinetic studies,
and the area under the concentr
45 gh concentrations of exposure in plasma by a
pharmacokinetic study,
and (3) reduce the tumor size of
46 ntology was demonstrated by annotating three
pharmacokinetics studies;
and the utility of the PK-corp
47 However, cochlear
pharmacokinetic studies are challenging due to small flu
48 During pediatric drug development, dedicated
pharmacokinetic studies are generally performed in all r
49 examethasone is used widely in oncology, but
pharmacokinetic studies are lacking.
50 Pharmacokinetic studies are therefore needed to define t
51 However,
pharmacokinetic studies are time-consuming, resource int
52 s, especially for supporting long-term human
pharmacokinetic studies,
are being raised.
53 Pharmacokinetic studies assessed in vivo differences in
54 During the 8-week study period,
pharmacokinetic studies assessed the bioequivalence of G
55 This
pharmacokinetics study assessed DMPA among HIV/TB co-inf
56 samples for SRI plasma levels were drawn for
pharmacokinetic studies before surgery and 1, 6, and 12
57 Subjects had
pharmacokinetic studies before transplantation and for u
58 To monitor silver concentrations,
pharmacokinetic studies can be performed.
59 d need to be carried out in parallel so that
pharmacokinetic studies can be undertaken as formulation
60 d rectal mononuclear cells from an intensive
pharmacokinetic study ("
Cell-PrEP" [preexposure prophyla
61 In this
pharmacokinetic study,
CF patients and control subjects
62 In a mouse
pharmacokinetics study,
compound 9t was brain-penetrant
63 prospective, sequence-randomized, replicate
pharmacokinetic study conducted at 5 US academic epileps
64 Ex vivo brain
pharmacokinetic studies confirmed the low in vivo PIB re
65 In the long-term
pharmacokinetic studies,
corneal CsA levels ranged from
66 In a single equivalent-dose
pharmacokinetic study,
DDCs enhanced the drug exposure b
67 Pharmacokinetic studies demonstrate that this compound i
68 Pharmacokinetic studies demonstrated 90% oral bioavailab
69 Detailed
pharmacokinetic studies demonstrated linear kinetics up
70 Pharmacokinetic studies demonstrated that BoNT/A was rap
71 Pharmacokinetic studies demonstrated that BX 471 was ora
72 In vivo
pharmacokinetic studies demonstrated that CD4-BFFI was s
73 Pharmacokinetic studies demonstrated that irinotecan cle
74 Pharmacokinetic studies demonstrated that the plasma con
75 Pharmacokinetics study demonstrated adipoRon (APN recept
76 Efficient and opportunistic
pharmacokinetic study designs, typically using sparse sa
77 in a rat model show no adverse events, and a
pharmacokinetics study documents a peak plasma concentra
78 For the phase 1 (
pharmacokinetic) study,
eligible patients had measurable
79 High throughput in vivo rodent cassette
pharmacokinetic studies enabled rapid validation of in v
80 Pharmacokinetic studies established that 13-d had proper
81 uation of circulating angiogenic factors and
pharmacokinetic studies failed to provide insight into t
82 Pharmacokinetic studies following subcutaneous administr
83 er in the 300-mg arm of the SSAT040 TMC278LA
pharmacokinetic study for rilpivirine (RPV) resistance.
84 Recent
pharmacokinetic studies have demonstrated that proton pu
85 We performed 24-hour intensive
pharmacokinetic studies in 111 women receiving efavirenz
86 Serial CSF samples were obtained for
pharmacokinetic studies in a subset of patients with Omm
87 nalization of drug therapies, as well as for
pharmacokinetic studies in both animals and humans.
88 Preliminary
pharmacokinetic studies in dog demonstrated excellent or
89 Implant A was used in long-term
pharmacokinetic studies in dogs aged more than 1 year.
90 11 studies of descriptive cohorts, and three
pharmacokinetic studies in end-stage renal disease, yiel
91 Pharmacokinetic studies in free-swimming adults revealed
92 Pharmacokinetic studies in human FcRn transgenic mice an
93 ternative to labeling with radioisotopes for
pharmacokinetic studies in humans.
94 e, synergism, P-glycoprotein inhibition, and
pharmacokinetic studies in in vitro and in vivo human an
95 bel for peptide hormones would be useful for
pharmacokinetic studies in infants, children, and pregna
96 Pharmacokinetic studies in male Sprague Dawley rats high
97 In
pharmacokinetic studies in mice and rats, increased plas
98 The system was tested for
pharmacokinetic studies in mice by quantifying myocardia
99 Pharmacokinetic studies in mice confirmed that FD&C Red
100 Pharmacokinetic studies in mice demonstrated that the le
101 Extensive in vitro screening and in vivo
pharmacokinetic studies in mice helped to identify two l
102 Pharmacokinetic studies in mice revealed that hSGZ exhib
103 In vivo
pharmacokinetic studies in mice show minimal uptake of p
104 In addition, toxicity and
pharmacokinetic studies in mice show significantly impro
105 Pharmacokinetic studies in mice showed a more than 1-log
106 valuate this possibility, we carried out MTX
pharmacokinetic studies in mice that received transplant
107 ons of 4 SHALs were labeled with (111)In for
pharmacokinetic studies in mice with HLA-DR10-expressing
108 Comparative
pharmacokinetic studies in mice with Raji B-cell lymphom
109 Employing oral
pharmacokinetic studies in mice, comparing drug levels i
110 Pharmacokinetic studies in mice, rats and dogs revealed
111 e model of cellular permeability and in vivo
pharmacokinetic studies in mice, thereby representing ad
112 Pharmacokinetic studies in normal and tumor-bearing rats
113 msstrahlung is less suitable for imaging and
pharmacokinetic studies in patients.
114 Pharmacokinetic studies in PC-3 xenograft SCID mice show
115 d showcase the racemization of the scaffold,
pharmacokinetic studies in preclinical species, and the
116 In vivo
pharmacokinetic studies in rabbit tear fluid showed sign
117 Furthermore,
pharmacokinetic studies in rats at 20 mg/kg indicated ex
118 Pharmacokinetic studies in rats demonstrated 3.3-fold hi
119 Pharmacokinetic studies in rats demonstrated that the pr
120 Pharmacokinetic studies in rats showed that 26 h was ora
121 Oral
pharmacokinetic studies in rats showed that ASD curcumin
122 Pharmacokinetic studies in rats showed that compound 32
123 Finally, in validation and
pharmacokinetic studies in rats, SOD outperformed other
124 a useful tool to avoid unnecessary dedicated
pharmacokinetic studies in the adolescent population dur
125 physicochemical, in vitro ADME, and in vivo
pharmacokinetic studies in the rat and the dog.
126 Pharmacokinetic studies in the rat indicate that, in con
127 Pharmacokinetic studies in the rat indicated that this c
128 Pharmacokinetic studies in the rat show 20 to be 42% ora
129 ated relatively low clearance in intravenous
pharmacokinetic studies in three species, and it is the
130 Following initial
pharmacokinetic studies in two pigs to determine desirab
131 Pharmacokinetic studies in vivo demonstrated that midazo
132 In addition,
pharmacokinetic studies in VWF knockout mice indicated t
133 essments regarding the need for an intensive
pharmacokinetic study in adolescents have been performed
134 A
pharmacokinetic study in experiment 2 showed that MH6-va
135 A
pharmacokinetic study in mice showed that GSK2801 had re
136 he promising dibenzoxepinone inhibitor 3i, a
pharmacokinetic study in mice was conducted.
137 n was further characterized in a single-dose
pharmacokinetic study in rat (t1/2 = 3.7 h; F = 86%) and
138 This method was successfully applied to the
pharmacokinetic study in rats for detection of GLB after
139 n following subcutaneous administration in a
pharmacokinetic study in rats.
140 plasma/tissues, and then examined in a full
pharmacokinetic study in rats.
141 Pharmacokinetics studies in rats showed that 16g was ora
142 ith human MDR1 gene (MDCK/MDR1), followed by
pharmacokinetics studies in rats.
143 Ultimately, a preliminary oral
pharmacokinetics study in male beagles showed that 28 is
144 A
pharmacokinetics study in rhesus monkeys of one of the I
145 asses of pharmacokinetics abstracts: in vivo
pharmacokinetics studies,
in vivo pharmacogenetic studie
146 Pharmacokinetic studies indicate high initial influx of
147 Current
pharmacokinetic studies indicate that approximately half
148 oses of rhuMAb VEGF were well tolerated, and
pharmacokinetic studies indicate that doses of > or = 0.
149 Tissue distribution and
pharmacokinetic studies indicated intestinal CFTR(inh)-1
150 Pharmacokinetic studies indicated that 3-CP in tumors wa
151 Pharmacokinetic studies indicated that compound 19 displ
152 Pharmacokinetic studies indicated that low oral bioavail
153 Pharmacokinetic studies indicated that the amount of sys
154 Pharmacokinetic studies investigated the tissue distribu
155 n the accuracy of LC/MS measurements used in
pharmacokinetic studies is examined.
156 28 patient reports or patient series, and 11
pharmacokinetic studies)
met inclusion criteria regardin
157 On the day of the
pharmacokinetic study,
minimum Concentration (Cmin), 12-
158 Neither in single-dose
pharmacokinetic studies nor the transplant recipients we
159 Population
pharmacokinetic studies of 58 patients demonstrated that
160 Pharmacokinetic studies of carboplatin were performed fo
161 In addition,
pharmacokinetic studies of CPT-11 and SN-38 in these ani
162 to progression, median survival, safety, and
pharmacokinetic studies of gemcitabine.
163 Pharmacokinetic studies of irofulven revealed dose-propo
164 ucture-activity-relationship studies and rat
pharmacokinetic studies of lead compounds are presented.
165 zamines is also presented in addition to the
pharmacokinetic studies of manzamine A (5).
166 Oral and intravenous
pharmacokinetic studies of manzamine A in rats indicated
167 Pharmacokinetic studies of N-myristoylalendronic acid re
168 The applicability of the methodology to
pharmacokinetic studies of PEITC in humans is demonstrat
169 The objective was to perform safety and
pharmacokinetic studies of purified unconjugated isoflav
170 Pharmacokinetic studies of released drugs after intraven
171 Plasma
pharmacokinetic studies of single-dose NSC23925b alone o
172 Pharmacokinetic studies of TFPI(C127 )in vivo demonstrat
173 In vivo
pharmacokinetic studies of the (111)In-DOTA-8-Aoc-BBN[7-
174 The
pharmacokinetic studies of the optimized formulation wer
175 Pharmacokinetic studies of U-50488 in plasma and brain w
176 Pharmacokinetic studies of vesnarinone revealed signific
177 s, deuterated 25(OH)D(3) (d-25[OH]D(3)) in a
pharmacokinetic study of 87 adults, including 43 with no
178 The method was applied to the
pharmacokinetic study of a mAb dosed in cynomolgus monke
179 A comparative
pharmacokinetic study of a nanoscale micellar docetaxel
180 A
pharmacokinetic study of an oral formulation (10 mg imme
181 The
pharmacokinetic study of DMA at oral and intravenous dos
182 A phase I and
pharmacokinetic study of IT mafosfamide was performed to
183 We conducted a 2-sample
pharmacokinetic study of oseltamivir in 12 premature inf
184 We report results of a phase I trial and
pharmacokinetic study of pemetrexed (LY231514) in childr
185 We conducted a 3-arm randomized,
pharmacokinetic study of tenofovir disoproxil fumarate (
186 Thus, we conducted a single-dose
pharmacokinetic study of TFV gel applied 1 or 24 hours b
187 We performed a phase I and
pharmacokinetic study of thalidomide with carboplatin in
188 We conducted a phase I and
pharmacokinetic study of the epidermal growth factor rec
189 A dose-escalation phase I and
pharmacokinetic study of the farnesyltransferase inhibit
190 A
pharmacokinetic study of the new HM administration metho
191 In the ILLUMENATE PK study (
Pharmacokinetic Study of the Stellarex Drug-Coated Angio
192 his LC-MS approach was also applied to a rat
pharmacokinetic study of the therapeutic monoclonal anti
193 On the basis of a previous
pharmacokinetic study of the use of intravenous ganciclo
194 Therefore, we initiated a phase I
pharmacokinetic study of this combination in our gastric
195 In vivo
pharmacokinetics studies of 7ii showed high liver distri
196 A
pharmacokinetics study of two mutant IgG2 antibodies wit
197 METHODS AND Published
pharmacokinetic studies on piperaquine were identified t
198 Pharmacokinetic studies on these agents in the mouse rev
199 on to their efficacy, we undertook the first
pharmacokinetic studies on these prodrugs.
200 In vivo
pharmacokinetics studies on 10 revealed slow absorption,
201 In the
pharmacokinetic study,
OROS-methylphenidate treatment pr
202 lanar and SPECT/CT imaging was performed and
pharmacokinetics studied over 2-3 d.
203 In vivo biodistribution and
pharmacokinetic studies performed using SKH1 hairless mi
204 The purpose of this
pharmacokinetic study performed in stable renal transpla
205 e LC-HRMS was then successfully applied to a
pharmacokinetic study performed on male Sprague-Dawley r
206 Pharmacokinetic studies revealed bioavailabilities of 2%
207 n 10(-9), a clinically acceptable level, and
pharmacokinetic studies revealed in vivo exposure levels
208 Pharmacokinetic studies revealed rapid absorption of Rh-
209 Pharmacokinetic studies revealed that 1294 is well absor
210 Pharmacokinetic studies revealed that 230 appears rapidl
211 The
pharmacokinetic studies revealed that about three times
212 Pharmacokinetic studies revealed that compound 57 had a
213 Our
pharmacokinetic studies revealed that intravenously admi
214 Pharmacokinetic studies revealed that it had a moderate
215 Pharmacokinetic study revealed that DC nanozymes signifi
216 ated by in vivo imaging technique and ocular
pharmacokinetics studies revealing that the clearance of
217 ntibody formats from both in vitro serum and
pharmacokinetic study samples.
218 Pharmacokinetic studies should be carried out to evaluat
219 The in vivo
pharmacokinetic studies showed a high level of receptor-
220 Pharmacokinetic studies showed a quick absorption of 2 i
221 Pharmacokinetic studies showed cyclosporin in the form o
222 Pharmacokinetic studies showed dose-independent clearanc
223 Pharmacokinetic studies showed inconsistent drug exposur
224 Pharmacokinetic studies showed pentostatin significantly
225 Pharmacokinetic studies showed rapid clearance of circul
226 Metabolism and
pharmacokinetic studies showed that 21 exhibited a plasm
227 Pharmacokinetic studies showed that 4c crosses the blood
228 Pharmacokinetic studies showed that 64Cu-TETA-OC was rap
229 Pharmacokinetic studies showed that anti-HER2/neu IgG3-(
230 In vivo
pharmacokinetic studies showed that miR-18a reaches the
231 tratracheally, and the blood cells from such
pharmacokinetic study showed good receptor occupancy of
232 The in-vivo
pharmacokinetic study showed that inhaled spray dried hy
233 Pharmacokinetics study showed that high Mw mP-PTX was cl
234 on efficiency was further confirmed from the
pharmacokinetic studies since the nanoporous mannitol ex
235 Structure-activity analyses and
pharmacokinetic studies suggest 15i as a promising antil
236 These results along with
pharmacokinetic studies suggest that 6j could be a promi
237 Pharmacokinetic studies suggest that lack of GSTM1 enzym
238 Pharmacokinetic studies suggested a long terminal half-l
239 Cellular and plasma
pharmacokinetic studies suggested dose proportionality b
240 Pharmacokinetic studies suggested that porcine skin derm
241 Previous
pharmacokinetic studies suggested that the unfavorable b
242 The present
pharmacokinetic study supports further trials to determi
243 acy data obtained during a previous phase II
pharmacokinetic study that compared combined ABZ plus PZ
244 In the short-term
pharmacokinetic studies,
the cornea had CsA concentratio
245 In the
pharmacokinetics studies,
the SND formulation increased
246 In a
pharmacokinetics study,
the blood concentrations of the
247 scopy, mass spectrometry and mechanistic and
pharmacokinetic studies,
there has been considerable int
248 They exhibit moderate oral exposure in rat
pharmacokinetic studies to achieve sufficient multiples
249 imaging examinations were supplemented with
pharmacokinetic studies to enable further assessment of
250 ildren should be developed early and used in
pharmacokinetic studies to guide dose selection.
251 In a dedicated
pharmacokinetic study to compare GFR with tubular secret
252 We conducted a
pharmacokinetic study to evaluate EFV trough concentrati
253 Participants received rFIX for
pharmacokinetic studies,
treatment of or prophylaxis aga
254 Pharmacokinetic studies using gnotobiotic mice revealed
255 Pharmacokinetic studies using LC-MS/MS analysis in male
256 Ocular
pharmacokinetic studies using MRI are noninvasive and pr
257 Moreover,
pharmacokinetic study using 2-in-1 micelles indicated th
258 luidic blood-counting system for preclinical
pharmacokinetic studies was developed.
259 The highest tumor uptake in
pharmacokinetic studies was obtained with LLP2A-DOTA and
260 In addition, a lung deposition and
pharmacokinetic study was conducted in rats to study dru
261 A Phase I safety and
pharmacokinetic study was conducted: a single subcutaneo
262 A Phase 1 safety and
pharmacokinetic study was conducted: a single subcutaneo
263 A
pharmacokinetic study was performed in 12 HIV-negative m
264 A prospective
pharmacokinetic study was performed in 12 recipients of
265 A
pharmacokinetic study was performed to determine the L d
266 99m radiolabeled human serum albumin, and a
pharmacokinetic study was performed.
267 d), two-sequence, crossover and steady-state
pharmacokinetic study was undertaken to compare twice-da
268 the applicability of the LC-MS/MS method for
pharmacokinetic studies,
we quantified rhTRAIL(WT) and r
269 Pharmacokinetic studies were also performed.
270 Pharmacokinetic studies were available for 79 patients.
271 In vivo
pharmacokinetic studies were carried out on hairless rat
272 Pharmacokinetic studies were conducted on day 1 to attai
273 Pharmacokinetic studies were done in wild-type and OATP1
274 mens for children required codification, and
pharmacokinetic studies were encouraged to develop optim
275 Pharmacokinetic studies were fitted to a linear, 2-compa
276 tuberculosis infection.Methods: Rifapentine
pharmacokinetic studies were identified though a systema
277 Additionally, in vivo
pharmacokinetic studies were implemented and the PRP's a
278 Pharmacokinetic studies were obtained for all patients.
279 Serial samples of CSF for
pharmacokinetic studies were obtained in a subset of pat
280 Pharmacokinetic studies were performed during course one
281 Pharmacokinetic studies were performed during the first
282 Pharmacokinetic studies were performed during the first
283 liter] x minutes) among patient cohorts, and
pharmacokinetic studies were performed for comparison.
284 Five phase 1, multiple-dose, open-label
pharmacokinetic studies were performed in 144 healthy vo
285 Feasibility and
pharmacokinetic studies were performed in nonhuman prima
286 The
pharmacokinetic studies were performed in Sprague-Dawley
287 Pharmacokinetic studies were performed on days 1 and 5 t
288 In vitro metabolism and initial
pharmacokinetic studies were performed on selected compo
289 Biodistribution and
pharmacokinetic studies were performed to determine the
290 Pharmacokinetic studies were performed with the initial
291 blind, placebo-controlled safety, tolerance,
pharmacokinetic studies were undertaken in a total of 12
292 Serial blood samples for thalidomide
pharmacokinetics studies were obtained after the first d
293 ecan exposure was achieved in seven of eight
pharmacokinetic studies when the topotecan plasma AUC wa
294 Rat
pharmacokinetic studies with compound 17 demonstrate low
295 Mouse
pharmacokinetic studies with oral administration of 23dd
296 Pharmacokinetic studies with RO-9187 in rats and dogs sh
297 Pharmacokinetic studies with the Mdr1a P-gp substrates l
298 In vivo pharmacodynamic and
pharmacokinetic studies with two examples, 12e and 12j,
299 d was applied successfully on the underlying
pharmacokinetic study with enhanced sample preparation t
300 dental exposures in younger children, where
pharmacokinetic studies would be difficult to conduct.